Journal Highlight : Immuno-Oncology
The journal welcomes scholarly contributions related to the interaction between the immune system and cancer, as well as the development and clinical application of immune-based strategies for cancer prevention, diagnosis, and treatment. This section focuses on research that advances the understanding of tumor–immune interactions and supports the development of innovative immunotherapeutic approaches in oncology.
The journal encourages submissions in areas including Cancer Immunology, Cancer Immunotherapy, Immune Checkpoint Inhibitors, CAR-T Cell Therapy, Tumor Microenvironment, Cancer Vaccines, Adoptive Cell Therapy, Monoclonal Antibody Therapy, Cytokine-Based Therapies, and Tumor Immune Evasion Mechanisms. Research related to Biomarkers in Immuno-Oncology, Immunogenomics, Precision Immunotherapy, Combination Immunotherapies, Oncolytic Viral Therapies, and Immune Response Monitoring is also welcomed.
Submissions focusing on Translational Immuno-Oncology, Clinical Trials in Cancer Immunotherapy, Predictive and Prognostic Immune Biomarkers, Resistance Mechanisms to Immunotherapy, AI and Bioinformatics in Cancer Immunology, Personalized Immunotherapy Approaches, and Immunotherapy Safety and Adverse Event Management are encouraged. The journal also welcomes studies investigating immune regulation in cancer progression, metastasis, and treatment response across various cancer types.
Accepted manuscript types include Original Research Articles, Systematic Reviews, Meta-Analyses, Experimental Studies, Translational Research Articles, Clinical Trial Reports, Case Reports, and Technology and Methodology Studies that contribute to advancements in immuno-oncology and cancer immunotherapy.
Through this focus area, the journal aims to support research that advances cancer immunology, improves the effectiveness and safety of immunotherapies, enhances personalized cancer treatment strategies, and contributes to innovative and evidence-based oncology care worldwide.
